Welcome to our dedicated page for GeneDx Holdings news (Ticker: WGS), a resource for investors and traders seeking the latest updates and insights on GeneDx Holdings stock.
GeneDx Holdings Corp. reports developments in genomic testing for rare disease diagnosis, with recurring updates on ExomeDx™ and GenomeDx™ testing, exome and genome test volumes, revenue growth, and full-year outlooks. The company uses GeneDx Infinity™, a rare disease genomic dataset, to support clinical interpretation, AI-enabled variant analysis, and biopharma discovery.
Company news also covers research publications and medical-meeting abstracts, health economics studies involving whole exome and whole genome sequencing, sponsored genetic testing programs for suspected rare diseases, and partnerships intended to expand access to genomic diagnosis. Updates frequently connect clinical data, sequencing technology, and rare disease patient identification with the company's precision-medicine operating model.
GeneDx (Nasdaq: WGS) reported strong Q2 2024 financial results, with revenue from continuing operations reaching $68.9 million, a 52% year-over-year increase. Exome and genome test revenue grew 77% to $50.7 million. Adjusted gross margin expanded to 62%, while adjusted net loss narrowed to $2.7 million. The company raised its full-year 2024 revenue guidance to $255-$265 million and reiterated its expectation to reach profitability in 2025.
Key highlights include a 52% year-over-year increase in exome and genome test volume, expanded Medicaid coverage for whole exome sequencing, and new collaborations to enhance access to rapid whole genome sequencing. GeneDx also announced reinvestment in whole genome sequencing products, improving turnaround times and sample collection methods.
GeneDx (Nasdaq: WGS) will report its financial results for the second quarter of 2024 after the market closes on Tuesday, July 30, 2024. A conference call to discuss these results will be held at 4:30 p.m. Eastern Time on the same day. Investors can register to listen to the call online, and a live and archived webcast will be available on the GeneDx investor relations website. GeneDx specializes in genomic insights, offering exome and genome tests to enhance personalized health care and drug discovery. For more information, visit genedx.com.
GeneDx (Nasdaq: WGS) has announced a collaboration with Epic to expand access to rapid whole genome sequencing (rWGS) services in neonatal intensive care units (NICUs). This integration will streamline access for health systems using Epic's electronic health records, improving provider and patient experiences. GeneDx aims to accelerate the adoption of rWGS services, which have seen an 80% year-over-year increase. The company highlights that 11 states now offer Medicaid coverage for rWGS, alongside growing commercial payor support. The collaboration will allow seamless integration of rWGS results into comprehensive medical records, enhancing patient care. GeneDx is also involved in the SeqFirst study at the University of Washington, investigating the impact of broad access to rWGS. The study aims to improve timely and effective treatments for critically ill infants. With over 600,000 exomes and genomes sequenced, GeneDx continues to lead in genomic insights, aiming to deliver better health outcomes.
GeneDx (Nasdaq: WGS) has announced a new patient access program to increase accessibility to exome sequencing for pediatric epilepsy patients. The program, developed with biopharma partners, aims to provide equitable care and overcome cost barriers for genetic testing. Exome testing, recommended as a first-line test by the National Society of Genetic Counselors and endorsed by the American Epilepsy Society, offers a nearly 25% diagnostic rate for epilepsy, higher than traditional multi-gene panels. Research indicates that genetic diagnoses can lead to up to 90% seizure reduction in some cases. The program will launch to select providers today, with full availability in July.
GeneDx (Nasdaq: WGS) announced its participation in two upcoming investor conferences in June 2024. The company will present at the Jefferies Healthcare Conference in New York City on June 5 at 9:00 a.m. ET and at the 44th Annual Goldman Sachs Global Healthcare Conference in Miami, Florida on June 10 at 3:20 p.m. ET. Live and archived webcasts of the presentations will be accessible on the GeneDx investor relations website. GeneDx focuses on delivering improved health outcomes through genomic insights and offers exome and genome tests to provide personalized health plans, accelerate drug discovery, and enhance health system efficiencies.
GeneDx Holdings Corp. (Nasdaq: WGS) reported first quarter 2024 revenue of $61.5M with 96% year-over-year growth in exome and genome test revenue. Expanded adjusted gross margins to 61%, narrowed adjusted net loss to $8.5M, and raised guidance to $235-$245M for FY 2024 revenue. GeneDx aims for profitability in 2025, showcasing a strong performance and strategic initiatives.
Summary not available.
Summary not available.
Summary not available.
Summary not available.